Climb Bio, Inc.
NASDAQ Global MarketTotal Valuation
Climb Bio, Inc. carries a market capitalization of 904.81M, placing it among publicly traded companies globally. Its enterprise value stands at 321.71M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 904.81M |
| Enterprise Value | 321.71M |
Share Statistics
Climb Bio, Inc. currently has 47.77M shares outstanding.
| Shares Outstanding | 47.77M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -1.42 |
| P/TBV Ratio | 2.91 |
| P/FCF Ratio | -8.10 |
| P/OCF Ratio | -8.08 |
Financial Position
Climb Bio, Inc. maintains a current ratio of 27.86, meaning it holds 27.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 27.86 |
| Quick Ratio | 26.91 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -29.90 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Climb Bio, Inc.'s stock has gained approximately 953.1746% over the past 52 weeks. The 50-day moving average sits at 11.07, while the 200-day moving average is 5.98.
| Beta (5Y) | N/A |
| 52-Week Price Change | 953.1746% |
| 50-Day Moving Average | 11.07 |
| 200-Day Moving Average | 5.98 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -59.94M, while operating income came in at -60.08M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -60.08M |
| Pretax Income | -52.79M |
| Net Income | -52.79M |
| EBITDA | -59.94M |
| EBIT | -60.08M |
| Earnings Per Share (EPS) | -0.84 |
Balance Sheet
Climb Bio, Inc. holds 109.56M in cash and equivalents against 479,000.00 in total debt, resulting in a net debt position of -8.36M. Total book value stands at -303.44M, with working capital of 109.33M providing operational flexibility.
| Cash & Cash Equivalents | 109.56M |
| Total Debt | 479,000.00 |
| Net Debt | -8.36M |
| Equity (Book Value) | -303.44M |
| Book Value Per Share | -4.82 |
| Working Capital | 109.33M |
Cash Flow
Climb Bio, Inc. produced -53.30M in operating cash flow over the past twelve months. After subtracting -109,000.00 in capital expenditures, free cash flow totaled -53.41M - equivalent to -0.85 per share.
| Operating Cash Flow | -53.30M |
| Capital Expenditures | -109,000.00 |
| Free Cash Flow | -53.41M |
| FCF Per Share | -0.85 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.00 |
| FCF Yield | -12.35 |
Scores
Climb Bio, Inc. posts an Altman Z-Score of 57.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 57.07 |